Last updated: November 5, 2026
Enzalutamide is one of the largest prostate-cancer drugs globally, with annual sales of roughly $5 billion across Pfizer and Astellas channels. Its commercial position rests on broad use across metastatic castration-resistant prostate cancer, nonmetastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. The principal financial risk is United States generic entry after the core patent estate expires in 2027, although regulatory exclusivity, patent litigation and launch settlements could delay broad substitution.
What is enzalutamide and how does it generate revenue?
Enzalutamide is an oral androgen-receptor signaling inhibitor marketed as Xtandi. It blocks androgen binding, androgen-receptor nuclear translocation and receptor-mediated gene transcription. The drug is administered with androgen-deprivation therapy in indicated disease settings.
The product is jointly commercialized:
| Region |
Primary commercial party |
Product |
| United States |
Pfizer |
Xtandi |
| Outside the United States |
Astellas Pharma |
Xtandi |
| Active ingredient |
Pfizer and Astellas |
Enzalutamide |
The companies developed enzalutamide under a global collaboration. Pfizer acquired Medivation, the original commercial owner, for approximately $14 billion in 2016. Astellas retained substantial rights through the original collaboration structure. [1]
Enzalutamide’s revenue base is diversified across several prostate-cancer treatment stages:
- Metastatic castration-resistant prostate cancer, or mCRPC
- Nonmetastatic castration-resistant prostate cancer, or nmCRPC
- Metastatic castration-sensitive prostate cancer, or mCSPC
- Combination use with androgen-deprivation therapy
The drug’s oral administration and established physician familiarity support continued use. Its main commercial weakness is increasing competition from newer androgen-receptor inhibitors and the availability of generic abiraterone.
What is the FDA regulatory status of Xtandi?
The FDA initially approved Xtandi in August 2012 for men with metastatic castration-resistant prostate cancer previously treated with docetaxel. Subsequent label expansions moved the drug into earlier disease settings.
| FDA milestone |
Indication or regulatory event |
| August 2012 |
Approval for metastatic CRPC after docetaxel |
| September 2014 |
Expansion to metastatic CRPC before chemotherapy |
| July 2018 |
Approval for nonmetastatic CRPC |
| November 2019 |
Approval for metastatic castration-sensitive prostate cancer |
| Ongoing |
Supplemental studies evaluating broader prostate-cancer use and combinations |
The FDA label specifies use with androgen-deprivation therapy unless the patient has undergone bilateral orchiectomy. The product is available as 40-milligram capsules and 80-milligram tablets, with a standard total daily dose of 160 milligrams. [2]
Enzalutamide does not face conventional biosimilar competition because it is a chemically synthesized small molecule rather than a biologic. Future competition will come through abbreviated new drug applications, or ANDAs, for generic enzalutamide.
How large is the enzalutamide market?
Global Xtandi sales have remained near or above $5 billion annually, placing the drug among the highest-revenue oral oncology products.
Astellas reports international Xtandi revenue in its fiscal-year disclosures, while Pfizer reports its United States share separately. Currency movements and fiscal-year differences make direct aggregation approximate.
| Metric |
Approximate position |
| Global annual brand sales |
About $5 billion |
| United States Pfizer revenue |
Approximately $1 billion to $1.5 billion annually |
| International Astellas revenue |
Approximately $3.5 billion to $4 billion annually |
| Principal commercial exposure |
United States and major European and Asian markets |
| Main loss-of-exclusivity risk |
United States generic entry from 2027 onward |
Astellas has continued to identify Xtandi as a core growth product, but the company also recognizes that the drug is approaching its principal patent-expiration period. Pfizer’s financial exposure is smaller in absolute terms because its rights are concentrated in the United States, but the U.S. market has high generic-substitution rates and can experience rapid price erosion after launch. [3,4]
What patents protect enzalutamide and Xtandi?
The principal U.S. patent estate is associated with the enzalutamide compound and related pharmaceutical compositions. The most frequently cited core patent is U.S. Patent No. 7,709,517.
| Patent |
Subject matter |
Approximate U.S. expiration |
| U.S. Patent No. 7,709,517 |
Enzalutamide compound and related claims |
September 2027 |
| U.S. Patent No. 8,183,274 |
Related enzalutamide composition and formulation claims |
Around 2027, subject to patent-term calculations |
| Additional listed patents |
Product, formulation or method-related protection |
Varies by claim and jurisdiction |
The effective exclusivity date can differ from the nominal patent expiration because of patent-term adjustment, pediatric exclusivity, terminal disclaimers, litigation outcomes and settlement agreements. The FDA Orange Book remains the controlling public source for patents listed against approved Xtandi formulations and should be reviewed against current FDA data before a launch decision. [5]
The patent estate is commercially meaningful but narrower than the estate for many biologic oncology products. Enzalutamide has no complex protein manufacturing process that would independently prevent generic entry. The primary barriers are patent claims, regulatory litigation and manufacturing scale.
When does enzalutamide lose exclusivity?
The principal U.S. patent cliff begins in 2027. A generic launch before the relevant listed patents expire would generally require one of four outcomes:
- A successful Paragraph IV challenge.
- A court ruling that the asserted patents are invalid or not infringed.
- A settlement permitting an earlier launch.
- A license or authorized-generic arrangement.
A pediatric extension, if applicable to the relevant listed patent, could shift the practical date into 2028. The exact commercial launch date also depends on ANDA approval, 30-month litigation stays, court orders and any confidential or public settlement terms.
Europe and other markets will not follow the U.S. timetable exactly. Supplementary protection certificates, national patent decisions, local reimbursement rules and country-specific launch strategies can extend or shorten the period of effective branded pricing.
Which companies are challenging enzalutamide patents?
Generic drug manufacturers have pursued ANDA filings for enzalutamide and have challenged listed Xtandi patents through Paragraph IV certifications. Publicly reported litigation has involved companies including Teva Pharmaceuticals and other generic applicants.
Paragraph IV litigation generally creates an automatic 30-month stay of FDA approval if the brand owner files suit within the statutory period. The stay delays approval, not necessarily commercial launch, and can end earlier through court judgment or settlement.
The commercial outcome depends on whether the generic applicant obtains:
- A judgment of invalidity
- A judgment of non-infringement
- A licensed early-entry date
- A launch subject to litigation risk
- A settlement with restrictions on marketing, manufacturing or supply
The existence of an ANDA challenge does not establish that generic enzalutamide will launch before 2027. It does establish that the market is being prepared for post-patent entry.
What is the Orange Book status of enzalutamide?
Xtandi is an FDA-approved small-molecule product listed in the Orange Book. Orange Book-listed patents can be challenged through Paragraph IV certifications. The relevant patent coverage centers on the active ingredient and approved product claims rather than a biologic exclusivity framework.
Regulatory exclusivity is less important than patent exclusivity for Xtandi at this stage. The product’s initial approvals are more than a decade old, and the commercial question is whether listed patents remain enforceable through the expected generic filing and launch period.
The Orange Book does not determine foreign patent rights, reimbursement protection or the practical speed of generic substitution. It is a U.S. regulatory-patent database, not a global freedom-to-operate opinion. [5]
How strong is the enzalutamide patent estate?
The estate has moderate commercial strength.
Strengths
- A clinically validated active ingredient with substantial revenue exposure.
- A core composition patent that reaches into the major commercial period.
- Multiple approved indications that increase the value of continued brand prescribing.
- Significant litigation economics for both the brand companies and generic applicants.
- High U.S. and international sales that support enforcement spending.
Weaknesses
- Small-molecule products are structurally exposed to conventional generic substitution.
- The core patent period is approaching its end.
- Generic abiraterone provides a lower-cost androgen-axis alternative.
- Newer androgen-receptor inhibitors compete for earlier-line treatment.
- Formulation and method-of-use patents may be less effective if generic labels omit protected indications.
The strongest claims are generally those that cover the active compound or unavoidable product characteristics. Method-of-use claims can be commercially weaker when generic applicants use skinny labeling, omit protected indications or rely on prescribing behavior outside the labeled use.
What formulations and methods of use are protected?
Xtandi has been marketed in multiple oral dosage forms, including capsules and tablets. Formulation protection may cover specific compositions, dosage forms, solid-state characteristics or manufacturing processes.
Method-of-use protection is relevant because enzalutamide has moved through several disease settings:
- Post-docetaxel mCRPC
- Chemotherapy-naive mCRPC
- nmCRPC
- mCSPC
A generic applicant may seek approval for all or only some approved indications. The applicant can attempt to avoid infringement by carving out patented methods from its label. In practice, physicians, payers and treatment guidelines determine how effective a label carve-out is.
The brand companies’ strongest commercial defense is therefore likely to combine compound patents, formulation claims, regulatory enforcement and market contracting rather than rely on one method-of-use claim.
How does enzalutamide compare with competing prostate-cancer drugs?
| Drug |
Company |
Mechanism |
Market position |
Generic or patent risk |
| Xtandi |
Pfizer/Astellas |
Androgen-receptor inhibitor |
Broad prostate-cancer use |
Major U.S. risk from 2027 onward |
| Erleada |
Johnson & Johnson |
Androgen-receptor inhibitor |
nmCSPC, nmCRPC and related use |
Later patent exposure than Xtandi, depending on patent |
| Nubeqa |
Bayer |
Androgen-receptor inhibitor |
nmCRPC, mCSPC and nonmetastatic hormone-sensitive disease |
Strong growth product, later life cycle |
| Zytiga |
Johnson & Johnson and generics |
CYP17 inhibitor |
Broad prostate-cancer use |
Generic abiraterone already available |
| Taxotere/docetaxel |
Sanofi and generics |
Taxane chemotherapy |
Established chemotherapy option |
Generic |
| PARP inhibitors |
Multiple companies |
DNA-repair pathway inhibition |
Biomarker-selected prostate cancer |
Narrower eligible population |
Enzalutamide has a wider historical treatment footprint than newer androgen-receptor inhibitors. Darolutamide has gained share through combination therapy and a favorable differentiation strategy, while apalutamide competes directly in earlier prostate-cancer settings.
Generic abiraterone places the greatest pressure on net prices. It is not a direct pharmacologic substitute in every patient, but payers can use it as a lower-cost androgen-axis option where clinical guidelines permit.
What licensing deals affect enzalutamide?
The core commercial agreement is the Pfizer-Astellas collaboration established before Pfizer’s acquisition of Medivation. The arrangement divides commercial rights by geography and has allowed both companies to monetize Xtandi without fully integrating global commercial operations.
The 2016 Medivation acquisition transferred Pfizer’s predecessor rights and strengthened Pfizer’s position in U.S. oncology. Astellas remained the principal international commercial partner. [1]
The structure reduces single-company revenue concentration but creates different incentives near loss of exclusivity. Pfizer faces a concentrated U.S. patent cliff. Astellas faces a broader international erosion curve, with country-specific timing and pricing effects.
What generic launch scenarios exist for enzalutamide?
Scenario 1: Delayed entry after patent expiry
Generic entry begins after the core U.S. patents expire, with multiple approved suppliers entering over several months. This is the baseline scenario if litigation does not produce an earlier launch.
Scenario 2: Settlement-based early entry
A generic company receives a license for an agreed date before nominal patent expiry. The agreement may include supply restrictions, authorized-generic provisions or limits on the number of entrants.
Scenario 3: At-risk launch
A generic launches after receiving FDA approval while patent litigation continues. This can create substantial damages exposure if the brand later prevails, but expected value may justify launch because the market is large.
Scenario 4: Partial indication entry
Generic companies enter with labels excluding certain patented uses. The practical impact depends on payer substitution, physician prescribing and enforcement of induced-infringement theories.
The first generic entrant can capture disproportionate value through 180-day generic exclusivity if it is the first successful Paragraph IV filer. Subsequent entrants generally accelerate price erosion.
What revenue exposure does the patent cliff create?
The United States represents a smaller share of total Xtandi revenue than international markets, but it is strategically important because U.S. generic substitution can be rapid. Pfizer’s direct revenue could decline sharply after generic launch even if total patient use remains stable.
A typical small-molecule oncology erosion pattern includes:
- Initial discounting by the first entrant
- Rapid payer-directed substitution
- Further price reductions as additional generics launch
- Continued branded use in selected patients and channels
- Lower international prices as national reimbursement systems respond
The global impact should be staged rather than modeled as a single-date collapse. International loss of exclusivity will occur country by country, while U.S. erosion could be much faster once several generic suppliers are available.
What is the competitive outlook for enzalutamide through 2030?
Before generic entry, enzalutamide should retain a large installed base because of clinical familiarity, broad indications and physician experience. Growth is likely to depend on treatment-line expansion, combination regimens and preservation of share against darolutamide and apalutamide.
After 2027, the product’s financial profile changes from growth oncology asset to cash-generating mature product. Brand companies can extend value through:
- New formulations
- Combination studies
- Earlier-line treatment
- Geographic expansion
- Contracting with payers
- Authorized-generic strategies
- Manufacturing and supply agreements
These measures can preserve volume but are unlikely to eliminate the core economic effect of generic competition.
Key Takeaways
- Enzalutamide is a roughly $5 billion global prostate-cancer franchise marketed as Xtandi.
- Pfizer controls the United States commercial business; Astellas controls most international commercialization.
- FDA approvals cover mCRPC, nmCRPC and mCSPC.
- The principal U.S. patent cliff begins around September 2027, with possible adjustment from pediatric exclusivity and litigation outcomes.
- Generic applicants, including publicly reported challengers such as Teva, have created Paragraph IV risk.
- Enzalutamide faces generic competition rather than biosimilar competition.
- Generic abiraterone already pressures pricing, while Erleada and Nubeqa compete for androgen-receptor inhibitor share.
- The strongest protection is tied to the active compound and unavoidable product claims. Method-of-use and formulation claims may be more vulnerable to label carve-outs.
- U.S. revenue is likely to erode faster than international revenue after generic launch.
- The most probable commercial path is continued high revenue before the patent cliff, followed by staged but material erosion from 2027 onward.
FAQs About Enzalutamide Market and Patent Risk
Is enzalutamide a biologic or a small-molecule drug?
Enzalutamide is a chemically synthesized small-molecule androgen-receptor inhibitor. Generic manufacturers can seek approval through the ANDA pathway rather than the biosimilar pathway.
What is the expected generic name for Xtandi?
The generic name is enzalutamide. Approved generic products would generally be labeled as enzalutamide capsules or tablets, subject to FDA approval and patent constraints.
Will generic enzalutamide be cheaper than generic abiraterone?
Pricing will depend on the number of entrants, payer contracts and launch timing. Generic enzalutamide is likely to face strong price pressure because generic abiraterone is already available as a lower-cost androgen-axis treatment.
Does Xtandi have pediatric exclusivity?
The potential effect of pediatric exclusivity depends on the specific patent and FDA-recognized exclusivity record. Any extension would affect the relevant listed patent, not necessarily every patent or every market.
Can a generic company launch enzalutamide before 2027?
It can launch earlier through a court victory, a settlement license, an authorized-generic arrangement or an at-risk launch. Without one of those outcomes, the core U.S. patent estate remains the primary barrier until its effective expiration period.
References
-
Pfizer Inc. (2016). Pfizer to acquire Medivation for $14 billion. Pfizer investor relations.
-
U.S. Food and Drug Administration. (2024). Xtandi (enzalutamide) prescribing information. FDA.
-
Astellas Pharma Inc. (2024). Annual report and financial results. Astellas Pharma Inc.
-
Pfizer Inc. (2024). Annual report. Pfizer Inc.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
